Detalhe da pesquisa
1.
Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent ß-Sparing PI3K Inhibitor in Rats, Dogs, and Humans.
Drug Metab Dispos
; 51(4): 436-450, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36623882
2.
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
Br J Clin Pharmacol
; 87(7): 2926-2936, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33336408
3.
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Drug Metab Dispos
; 47(9): 966-973, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31266752
4.
Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Pharm Res
; 35(12): 244, 2018 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30367284
5.
Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Pharm Res
; 35(12): 233, 2018 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30324422
6.
Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Biopharm Drug Dispos
; 39(9): 420-430, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30335192
7.
Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.
J Lipid Res
; 57(1): 46-55, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26522778
8.
A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma.
Biomed Chromatogr
; 30(12): 1984-1991, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27245274
9.
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Clin Transl Sci
; 17(3): e13769, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515348
10.
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 12(8): 832-838, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145975
11.
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors.
CPT Pharmacometrics Syst Pharmacol
; 12(1): 95-109, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36330700
12.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Leuk Lymphoma
; 64(2): 329-338, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36480811
13.
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
Biomedicines
; 9(9)2021 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34572463
14.
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Pharmacol Res Perspect
; 9(6): e00870, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664792
15.
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
CPT Pharmacometrics Syst Pharmacol
; 10(5): 441-454, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33687157
16.
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
Leuk Lymphoma
; 62(11): 2612-2624, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159878
17.
Human Mass Balance and Metabolite Profiling of [14 C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.
Clin Pharmacol Drug Dev
; 10(9): 1108-1120, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876576
18.
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Cancer Chemother Pharmacol
; 88(1): 81-88, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772633
19.
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Clin Transl Sci
; 14(2): 764-772, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306268
20.
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment.
Leuk Lymphoma
; 61(6): 1355-1363, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32031037